advertisement

NeoGenomics Laboratory Company Overview Presentation 02/19/2014

75 %
25 %
advertisement
Information about NeoGenomics Laboratory Company Overview Presentation 02/19/2014
Health & Medicine

Published on February 19, 2014

Author: NeoGenomics

Source: slideshare.net

Description

In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:

•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals

•Strategic client partnerships created by “Tech-Only” model

•Dynamic, rapidly-growing and consolidating industry

•Industry-leading revenue & test volume growth

•Strong productivity and operating leverage leading to accelerating cash flow and net income

•Strong Management Team with large cap lab experience
advertisement

NASDAQ: NEO Time Matters. Results Count! Company Overview Presentation February 2014 “Improving Patient Care through exceptional cancer genetic testing services!” 1

Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forwardlooking statements. Investors and prospective investors are cautioned that any such forwardlooking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events. 2

Investment Highlights • Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals • • • • Strategic client partnerships created by “Tech-Only” model • Strong Management Team with large cap lab experience Dynamic, rapidly-growing and consolidating industry Industry-leading revenue & test volume growth Strong productivity and operating leverage leading to accelerating cash flow and net income 3

Consistent Historical Growth Annual Revenue ($, 000s) Tests Performed 2013 2012 2011 2010 2009 0 2008 $0 2007 20,000 2006 $10,000 2005 40,000 2004 $20,000 2013 60,000 2012 $30,000 2011 80,000 2010 $40,000 2009 100,000 2008 $50,000 2007 120,000 2006 $60,000 2005 140,000 2004 $70,000 4

Accelerating Cash Flow & Earnings ($, 000's) 2011 2012 2013 $ 43,484 26.5% $ 59,867 37.7% $ 66,467 11.0% Total Gross Margin Gross Margin % 19,428 44.7% 26,836 44.8% 31,737 47.7% Sales & Marketing Exp as a % of Rev Gen & Admin Exp as a % of Rev R&D Exp as a % of Rev SG&A Expenses Total SG&A as a % of Rev 16.0% 28.4% 1.2% 19,837 45.6% 12.5% 26.5% 3.8% 25,624 42.8% 13.1% 26.2% 3.7% 28,563 43.0% Total Revenue % Growth Adjusted EBITDA % Growth $ 2,134 NA $ 5,997 181.0% $ 8,515 42.0% Net Income/(Loss) Diluted EPS $ (1,177) ($0.03) $ 65 $0.00 $ 2,034 $0.02 Summary Operating Metrics Avg. Revenue/Test % Change $ 570 -4.9% $ 522 -8.4% $ 484 -7.3% $ 315 -2.7% $ 288 -8.6% $ 253 -12.2% Avg. Cost of Goods Sold/Test % Change 5

Management Team • Douglas VanOort, Chairman & CEO • Maher Albitar, M.D., Chief Medical Officer & Director of R&D • Robert Gasparini, Director & Chief Scientific Officer • Steven Jones, Director, EVP – Finance, & Chief Compliance Officer • George Cardoza, Chief Financial Officer • Robert Horel, Vice President, Sales & Marketing • Steven Ross, Chief Information Officer Operating Partner, Summer Street Capital Partners; Chief Operating Officer, Quest Diagnostics Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute; Director of Leukemia and Molecular Laboratory, MD Anderson Cancer Center Director of Genetics, U.S. Labs; Worldwide Marketing Mgr., Ventana Medical Systems; Asst. Director, Prenatal Diagnostic Center (Harvard) Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners; Vice President, Merrill Lynch Investment Banking CFO, Protocol Global Solutions; Controller, Central Region, Quest Diagnostics Regional Mgr., US Labs; Product Specialist, Ventana Medical Systems; Pilot, U.S. Navy Vice President Technology, Chico’s FAS, Inc. 6

NeoGenomics’ Cancer Testing Services Key Testing Methodologies Cytogenetics: chromosome analysis - “Neighborhood view of 46 houses from 1000 feet” Flow Cytometry & IHC: cell surface marker analysis - “Single house view from 500 feet” Fluorescence in-situ Hybridization (FISH): gene analysis - “Door and window view of one house” Molecular testing: DNA/RNA analysis -“View of serial number on door lock” 7

Customer Targets Pathologists & Hospital Pathology Groups (about 72% of Revenue) • • • Enable community Pathologists to practice using sophisticated tools and tests Innovative technical component (TC or “tech-only”) services – Flow, FISH, IHC Outstanding Web-based Lab System & extensive training programs Oncologists & Clinician Groups (about 25% of Revenue) • Includes Hematologists, Oncologists, Dermatologists, Urologists • Disease Panels and comprehensive molecular menus • Increasing Opportunity to service larger practices with Tech-only model Clinical Trials & Other (about 3% of Revenue) • Contract research/clinical trial support work for Pharma clients 8

NeoGenomics Formula for Success Industry Dynamics & Demographics • Aging U.S. population and prevalence of cancer • Diagnostic testing reduces healthcare costs and improves clinical outcomes • Emergence of molecular diagnostics • Targeted therapeutics and companion diagnostics • Capitalize on new healthcare paradigm Market Share Gains • Attract New Customers – Promote key advantages of “tech-only” model – Partner with Clinician Offices • Grow existing customer base New Products & Solutions • Continue to expand test menu • Sublicensing of HDC products – Cytogenetics/Flow/IHC systems – Prostate/colon/pancreatic Cx Tests – International opportunities – Sales force productivity • Proprietary test development – Increase share of wallet • Disruptive technology for select solid tumor cancers – Promote product education – Capitalize on competitor turmoil • Seek new R&D partnerships Superior Financial Model • Sustainable revenue growth opportunity • Significant degree of operating leverage in the business model 9

Industry Dynamics – Molecular diagnostics enable physicians to better diagnose diseases and predict therapeutic efficacy • – Clinical Benefits: Effective treatment at an early stage increases patient survival rates • Healthcare Savings: a) forego spending on ineffective therapies and b) effective intervention at an early stage generally lowers overall treatment cost Need for companion diagnostics being driven by rising drug costs and an increase in targeted therapeutics • • Xalkori® (Crizotinib) - Cost of ~$90,000 annually to treat non-small cell lung cancer. 50 – 61% effective for the ~3% of the population with certain genetic characteristics U.S. Population Demographics Diagnostic testing can significantly lower healthcare costs and improve clinical outcomes – • Boomer Impact on Cancer Market Molecular diagnostics transforming lab services industry and fueling rapid growth Diagnostics represents only 2-3% of total healthcare spend but influence approximately 70% - 80% of physician decisions Cancer prevalence expected to increase as U.S. population ages – 77% of all cancers diagnosed are in people age 55 or older, the fastest growing segment of the US 30% Current 25% Percent Of Population • 20% 20% 20% 2030 2040 2050 22% 16% 17% 18% 16% 15% 10% 26% 19% 25% 25% 16% 11% 13% 12% 13% 1990 2000 2010 5% 0% 1980 Age 60 and older 2020 Age 65 and older 10

U.S. Cancer Testing Market Size $10-12 Billion Hematopoietic Cancers Solid Tumor Cancers $3 - 4 Billion $7 - 8 Billion ~$2 - 3 Billion ~$2 - 3 Billion Patients in Treatment: 850,000 7.0 million New Diagnoses/Yr.: 150,000 1.45 million Bone Marrow (350K/Yr) Per. Blood (150K/Yr) Lymph Nodes Tiss. Biopsies (8-10MM) Fine Needle Aspirates Other Bodily Fluids ~80% ~20% Total Testing Market: Est. Genetic Mkt. (TAM) Specimen Types: Neo Revenue Split: 11

Cancer Testing Market Characteristics • Cancer Genetics is high growth segment of lab Industry - ~15-20% annual test volume growth in genetics testing - ~6-8% annual test volume growth in related AP testing • Less than 400 Cancer Genetic Labs in the U.S. - 2/3 affiliated with academic institutions - Approximately 20% perform 80% of testing - Only 15-20 labs with national reach • High pace of consolidation - Recent examples include: Target Caris Diagnostics Genoptix Clarient Genzyme Genetics Acquiror Miraca Novartis GE Healthcare Svcs LabCorp TV/LTM Rev 3.5x 1.7x 5.8x 2.5x 12

A Growing Commercial & Facility Footprint VT WA ME MT ND MI NH MN OR ID NY SD WI MI WY IA NE IL CO CA KS IN MO WV AZ KY SC AR NM MS TX CT VA NC OK RI NJ DE MD OH NV UT PA MA AL GA LA Irvine, CA 18k sf FL States sending specimens in 2013 Nashville, TN 7k sf Tampa, FL 5k sf Ft. Myers, FL 45k sf 13

Accelerating Pace of Innovation 2011 4 molecular tests 2012 2013 10-color Flow Cytometry 40 new Molecular tests Add’l NeoTYPE Panels 3 FISH Implemented State-of-the-art MolDx platform in lieu of Kits 28 new Molecular Assays ROS1 FISH FL – IHC menu Proprietary method for increasing sensitivity of Sanger sequencing 7 NeoTYPE MolDx Panels Plasma/Urine-based Prostate Test (Patent App) New Aperio Digital Image Analysis SVM for FISH (Patent App) Barrett’s Esoph. FISH (Patent App) NeoARRAY/SNP Cytogenetics Internalized 99% of send-outs Next Generation Sequencing (48 genes) NeoSITE Melanoma FISH SVM-based Cytogenetics Analysis System SVM-based Automated FISH Analysis System v2 14

More than 80 New Assays Launched in 2012 & 2013 Solid Tumor Assays* Molecular Assays: 1. IDH1 & IDH2 Mutation Analysis 2. c-KIT Mutation Analysis 3. PIK3CA Mutation Analysis 4. NRAS Mutation Analysis 5. TP53 Mutation Analysis 6. NeoARRAY SNP/Cytogenetic Profile 7. KRAS Mutation Analysis 8. BRAF Mutation Analysis 9. EGFR Mutation Analysis 10. Microsatellite Instability Analysis 11. NeoTYPE Breast Profile 12. NeoTYPE Colorectal Profile 13. NeoTYPE Gastric Profile 14. NeoTYPE Lung Profile 15. NeoTYPE Solid Tumor (Other) Profile 16. TPMT Genotyping 17. UGT1A1 Genotyping 18. Kit/PDGFRa Mutation Analysis 19. HRAS Mutation Analysis 20. PTEN Mutation Analysis 21. HOXB13 Genotyping 22. GNAS Mutation Analysis 23. MLH1 Promoter Methylation Analysis 24. MGMT Promoter Methylation Analysis FISH/ISH Assays: 1. ISH – Kappa ISH 2. ISH – Lambda ISH 3. NeoSITE Barrett’s Esophagus FISH 4. ROS1 FISH 5. NeoSITE Melanoma FISH 6. 1p/19q Deletion FISH Test Hematopoietic Assays* Molecular Assays: 1. BCR-ABL1 Translocation, t(9;22) 2. ABL1 Kinase Domain Mutation Anal 3. IgVH Mutation Analysis 4. FLT3 Mutation Analysis 5. NPM1 Mutation Analysis 6. JAK2 V617F Mutation Analysis 7. JAK2 Exon 12-14 Mutation Anal 8. BCL2 Translocation, t(14;18) 9. BCL1 Translocation, t(11;14) 10. MPL Mutation Analysis 11. MPN Reflex Panel 12. DNMT3A Mutation Analysis 13. RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) 14. SF3B1 Mutation Analysis 15. B-Cell Gene Rearrangement 16. T-Cell Gene Rearrangement 17. CBFB/MYH11 Translocation, inv(16) 18. PML-RARA Translocation, t(15;17) 19. CEBPA Mutation Analysis 20. WT1 Mutation Analysis 21. NeoTYPE CLL Prognostic Profile 22. NeoTYPE AML Prognostic Profile 23. ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21) 24. CARD11 Mutation Analysis 25. CD79B Mutation Analysis 26. MYD88 Mutation Analysis 27. RUNX1 Mutation Analysis 31. NOTCH1 Mutation Analysis 32. EZH2 Mutation Analysis 33. Chimerism/DNA Fingerprinting Analysis 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. TET2 Mutation Analysis CBL Mutation Analysis ASXL1 Mutation Analysis PTPN11 Mutation Analysis CSF3R Mutation Analysis PTPN11 Mutation Analysis STAT3 Mutation Analysis ETV6 Mutation Analysis NeoTYPE Lymphoma Profile NeoTYPE MDS/CMML Profile NeoTYPE Spliceosome Profile FISH/ISH Assays: 1. NHL FISH Panel (Revised) 2. MYC/IgH t(8;14) 3. CLL FISH Panel (Revised) 4. MDS FISH Panel (Revised) 5. MPN FISH Panel (Revised) 6. AML FISH Panel (Revised) 7. Eosinophilia FISH Panel 8. IGH/MAFB FISH 9. PTEN FISH BOLD = Multi-assay tests customizable to meet client needs (assays may also be ordered individually). * Certain assays may be useful in both solid tumor and hematopoietic cancers. Each assay listed in area of primary use. 15

Key Growth Drivers Over the Next 3 Years • Expansion of Sales Team with seasoned Professionals • Growth of molecular assays, panels and Next Gen Sequencing • Recent expansion in FISH and advanced flow cytometry • New Image Analysis/Immunohistochemistry Platform • Exclusive strategic alliance with Covance for Clinical Trials • Proprietary NeoSCORE Prostate Cancer and other proprietary tests • M&A Opportunities 16

Increasing Margins Despite Lower Average Unit Prices 100% 56.5% 60% 90% 50% 80% 40% 70% 30% 60% 20% 50% 47.1% 47.2% 47.3%48.4% 46.1% 46.3% 45.9% 48.4% 44.8% 45.2% 43.2% 44.5% 44.6% 43.9% 44.7% 41.5% 50.0% 10% 40% 0% 30% -10% 20% -20% Gross Margin % Cum Change in Avg Rev/Test(2) Q3 13 Q2 13 Q1 13 Q4 12 Q3 12 Q2 12 Q1 12 Q4 11 Q3 11 Q2 11 Q1 11 Q4 10 Q3 10 Q2 10 Q1 10 Q4 09 0% Q4 13 -23.4% 10% -30% -40% Cum Change in Productivity(1) (1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE. (2) The expiration of the Medicare Technical Component (TC) Grandfather Clause took effect on 7/1/12 and resulted in an ~11% YoY Reduction in Avg Rev/Test. 17

Cost Management & Operating Leverage Operating Cost per Test & Adj. EBITDA Margin $800 20% $723 $700 $642 $642 $671 $649 15% $618 $576 $565 $600 $500 5% $400 $300 -1% $200 0% -2% 6% 12% $555 8% 12% $531 $512 $526 6% 10% 11% 12% 13% $482 $478 $464 $466 $439 10% 5% 0% -1% -5% -5% -10% $100 $0 15% -12% -15% Q409 Q110 Q210 Q310 Q410 Q111 Q211 Q311 Q411 Q112 Q212 Q312 Q412 Q113 Q213 Q313 Q413 Cogs Cost/Test R&D Cost/Test G&A Net of R&D Cost/Test Total Cost/Test S&M Cost/Test Adj EBITDA Margin % 18

Quarterly Financial Information ($, 000's) Q4 12 * Q1 13 * Q2 13 * Q3 13 Q4 13 Total Revenue % Growth (YoY) $ 14,893 15.5% $ 15,657 3.3% $ 15,603 -0.1% $ 16,884 18.9% $ 18,323 23.0% Total Gross Margin Gross Margin % 6,434 43.2% 7,246 46.3% 7,157 45.9% 8,171 48.4% 9,163 50.0% Sales & Marketing Exp General & Administrative Exp Research & Development Exp 1,692 4,097 448 1,931 4,175 835 1,971 4,064 616 2,336 4,334 340 2,487 4,823 649 6,237 41.9% 6,942 44.3% 6,651 42.6% 7,011 41.5% 7,959 43.4% Total SG&A (Incl R&D) Expenses SG&A as a % of Rev Net Income/(Loss) Diluted EPS $ (113) ($0.00) Adjusted EBITDA $ 1,439 $ 1,794 $ 1,825 $ 2,163 $ 2,733 Summary Operating Data % Growth in Tests Performed (YoY) Avg. Revenue/Test Avg. COGS/Test 35.3% $ 488 $ 277 19.1% 488 $ $ 262 12.7% $ 480 $ 260 19.1% $ 501 $ 258 27.8% $ 470 $ 235 $ 3 $0.00 $ 273 $0.01 $ 900 $0.02 $ 858 $0.02 * YoY comparisons impacted by a reduction in revenue of $1.3 MM/Qtr as a result of the expiration of the TC Grandfather Clause. 19

Key Financial Information Recent Share Price (2/18/14): $ 3.86 Common Shares Outstanding: 49.1 M Current Market Cap: $189.0 M Fully Diluted Shares: 55.8 M 52 Week Low/High: $2.05/$4.69 Avg. Daily Trading Volume (3 Mos): 279,682 20

NeoGenomics Summary • • • • • Emerging leader in fastest-growing segment of lab testing industry Robust competitive advantages and product portfolio Strong Management Team with outstanding industry experience Accelerating profitability driven by growth and operating leverage Recent Guidance(1): Q1 2014(2) FY 2014(2) Revenue ($, MMs) $18.8 - $19.3 $73.0 - $77.0 EPS $0.01 – $0.02 $0.05 - $0.07 (1) Guidance is before factoring any potential impacts from a negative resolution of the issues re the National Correct Coding Initiative FISH edits. See 8-K filed on 2/19/2014 for additional information on this topic. (2) NeoGenomics preliminarily estimates that a negative resolution of the NCCI FISH edits issue would reduce revenue by approximately $3 million and net income by approximately $0.04 per share in FY 2014, with the impact more heavily concentrated in the first half of the year. Q1 revenue and EPS would be reduced by approximately $1.0 million and $0.02/share in the event of a negative resolution. 21

Implied 2014 Physician Fee Schedule Rates Based on our 24% Medicare payer mix through the first 9 months of 2013, we expect the Medicare 2014 PFS Rates to have less than a 3% impact to total revenue (1). CPT Proc Code Procedure Description National National National Unadj Rate Unadj Rate Unadj Rate 2013 2011 2012 88184 88185 88189 FLOW 1ST MARKER $ $ $ 83.92 $ 50.29 $ 103.29 $ 82.71 $ 50.04 $ 102.45 $ 88.80 54.10 106.49 $ $ $ 87.77 53.73 110.69 -1.2% -0.7% 3.9% 88367 88367-TC 88367-26 FISH AUTOMATED PER PROBE $ $ $ 256.18 $ 195.36 $ 60.82 $ 264.13 $ 203.89 $ 60.25 $ 258.23 198.35 59.88 $ $ $ 255.77 193.08 62.69 -1.0% -2.7% 4.7% 88368 88368-TC 88368-26 FISH MANUAL PER PROBE $ $ $ 219.83 $ 157.65 $ 62.18 $ 221.24 $ 159.98 $ 61.27 $ 232.04 170.46 61.58 $ $ $ 232.49 167.65 64.84 0.2% -1.6% 5.3% 88360 88360-TC 88360-26 MORPHOLOGY, EACH ANTIBODY MANUAL $ $ $ 123.33 $ 71.01 $ 52.32 $ 120.49 $ 69.44 $ 51.06 $ 127.25 74.85 52.40 $ $ $ 130.04 75.23 54.81 2.2% 0.5% 4.6% 88342 88342-TC 88342-26 IMMUNOHISTOCHEMISTRY $ $ $ 103.92 $ 62.86 $ 41.11 $ 105.52 $ 64.67 $ 40.85 $ 115.34 73.15 42.19 G0461 GO461-TC G0461-26 IMMUNOHISTOCHEMISTRY (1st Stain) $ $ $ 103.92 $ 62.86 $ 41.11 $ 105.52 $ 64.67 $ 40.85 $ 115.34 73.15 42.19 $ $ $ 88.48 57.67 30.81 -23.3% -21.2% -27.0% G0462 GO462-TC G0462-26 IMMUNOHISTOCHEMISTRY (Add'l Stain) $ $ $ 103.92 $ 62.86 $ 41.11 $ 105.52 $ 64.67 $ 40.85 $ 115.34 73.15 42.19 $ $ $ 68.42 55.88 12.54 -40.7% -23.6% -70.3% FLOW EACH ADDL MARKER FLOW INTERP 16 OR MORE MARKERS FISH AUTOMATED PER PROBE TECH FISH AUTOMATED PER PROBE INTERP FISH MANUAL PER PROBE TECH FISH MANUAL PER PROBE INTERP MORPHOLOGY TECH, EACH ANTIBODY MANUAL MORPHOLOGY INTERP, EA ANTIBODY MANUAL IMMUNOHISTOCHEMISTRY TECH IMMUNOHISTOCHEMISTRY INTERP IMMUNOHISTOCHEMISTRY TECH (1st Stain) IMMUNOHISTOCHEMISTRY INTERP (1st Stain) IMMUNOHISTOCHEMISTRY TECH (Add'l Stain) IMMUNOHISTOCHEMISTRY INTERP (Add'l Stain) 2014 w/ 2014 vs Interim SGR 2013 % Fix (1)(2) change (1) Assumes no other Physician Fee Schedule (PFS) rule changes or limited coverage determinations for 2014. (2) Calculated using a 2014 CMS Conversion Rate of 35.8228 as enacted in the 'Pathway for SGR Reform Act of 2013’ on December 26, 2013. This SGR Fix is only in effect to 3/31/14 unless extended further by Congress. 22

Add a comment

Related presentations

Related pages

NeoGenomics Laboratory | Cancer Reference laboratory

NeoGenomics is a specialized in Cancer ... NeoGenomics Laboratories is a specialised cancer genetic diagnostics reference laboratory with ... Overview ...
Read more

Investor Relations Overview — Investor Relations ...

Investor Relations: ... Company Overview Presentation. Download our Company Overview. Company Overview Presentation Nov 2015 from NeoGenomics Laboratory ...
Read more

NeoGenomics Company Information

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies, ... Overview; Resources for Common ...
Read more

NeoGenomics Laboratories | LinkedIn

See who you know at NeoGenomics Laboratories, leverage your professional network, ... Company overview presentation of NeoGenomics..... Like (8) Like (8)
Read more

NeoGenomics (@NeoGenomics) | Twitter

... (@NeoGenomics). ... NeoGenomics Company Overview 05/26/2015 http ... NeoGenomics Laboratories DNA sequencing for BTK Inhibitor Resistance and ...
Read more

NeoGenomics provides laboratory tests focused on cancer ...

NeoGenomics operates cancer testing laboratories serving ... to your left for the latest Investor Presentation for NeoGenomics ... Company Overview
Read more

NeoGenomics Amends Strategic Alliance Agreement with ...

... the fastest growing segment of the laboratory industry. The company's ... FL, NeoGenomics has laboratories ... its Company Overview Presentation ...
Read more